Sign Up Today and Learn More About Mercy BioAnalytics Stock
Invest in or calculate the value of your shares in Mercy BioAnalytics or other pre-IPO companies through EquityZen's platform.
Mercy BioAnalytics Stock (MERB)
Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.
About Mercy BioAnalytics Stock
Founded
2018
Headquarters
Natick, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Mercy BioAnalytics Press Mentions
Stay in the know about the latest news on Mercy BioAnalytics
Mercy BioAnalytics: $59 Million Closed To Advance Early Cancer Detection With Liquid Biopsy
pulse2 • Sep 12, 2025
Mercy BioAnalytics Raises $59 Million In Series B
citybiz • Sep 12, 2025
Mercy BioAnalytics Announces $59 Million Series B Financing to Advance Early Cancer Detection Programs
vcaonline • Sep 04, 2025
Cancer Early Detection Firm Mercy BioAnalytics Closes $59M Series B Round
genomeweb • Sep 04, 2025
Mercy BioAnalytics Appoints Dr. Prasanth Reddy as Chief Medical Officer
citybiz • Jul 09, 2025
Mercy BioAnalytics Management
Leadership team at Mercy BioAnalytics
CSO & Co-Founder
Joseph Sedlak
Chief Operating Officer
Dawn Mattoon
Join now and verify your accreditation status to gain access to:
- Mercy BioAnalytics Current Valuation
- Mercy BioAnalytics Stock Price
- Mercy BioAnalytics Management
- Available deals in Mercy BioAnalytics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Mercy BioAnalytics Cap Table and Funding History by Share Class and Liquidity Preferences
- Mercy BioAnalytics Revenue and Financials
- Mercy BioAnalytics Highlights
- Mercy BioAnalytics Business Model
- Mercy BioAnalytics Risk Factors
- Mercy BioAnalytics Research Report from SACRA Research
Trading Mercy BioAnalytics Stock
How to invest in Mercy BioAnalytics stock?
Accredited investors can buy pre-IPO stock in companies like Mercy BioAnalytics through EquityZen funds. These investments are made available by existing Mercy BioAnalytics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Mercy BioAnalytics stock?
Shareholders can sell their Mercy BioAnalytics stock through EquityZen's private company marketplace. EquityZen's network includes over 400K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 49K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
